Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.64 USD
Change Today -0.02 / -1.20%
Volume 1.1M
GALE On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Mark W. Schwartz Ph.D.

Chief Executive Officer, President, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee, Galena Biopharma, Inc.
AgeTotal Calculated CompensationThis person is connected to 20 board members in 2 different organizations across 4 different industries.

See Board Relationships
60$1,014,762
As of Fiscal Year 2014

Background*

Dr. Mark W. Schwartz, Ph.D., has been the Chief Executive Officer and President of Galena Biopharma, Inc. since August 2014. Dr. Schwartz served as the Chief Operating Officer and Executive Vice President at Galena Biopharma, Inc., since April 2011 until August 2014. Dr. Schwartz served as the Chief Executive Officer and President at Apthera, Inc. since January 2010. Dr. Schwartz served as the Chief Executive Officer and President of Bayhill Therapeutics Inc. from March ...

Read Full Background

Corporate Headquarters*

4640 SW Macadam Avenue
Portland, Oregon 97239

United States

Phone: 855-855-4253
Fax: 503- 400-6611

Board Members Memberships*

2014-Present
Chief Executive Officer, President, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee
2014-Present
Director

Education*

PhD
Arizona State University-Tempe
BA
Grinnell College

Other Affiliations*

Annual Compensation*

Salary$419,105
Bonus$288,000
Total Annual Compensation$707,105

Stock Options*

All Other Compensation$1,477
Exercisable Options628,535
Unexercisable Options611,465
Total Number of Options1,240,000

Total Compensation*

Total Annual Cash Compensation$708,582
Total Short Term Compensation$707,105
Other Long Term Compensation$1,477
Total Calculated Compensation$1,014,762
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GALE:US $1.64 USD -0.02

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive (leave of absence) and Director
Silence Therapeutics plc
200.0K GBP
Mark A. Sirgo Pharm.D.Chief Executive Officer, President, Chief Scientific Officer, Executive Director and Member of Executive Subcommittee
BioDelivery Sciences International, Inc.
$751.4K
Peter French B.Sc, M.Sc, Ph.D., MBAChief Executive Officer, Managing Director and Director
Benitec Biopharma Limited
A$450.0K
Mark Joseph Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$580.0K
Paul C. Grint M.D.Chief Executive Officer, President and Director
Regulus Therapeutics Inc.
--
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALENA BIOPHARMA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.